Curatis Reports Revenue Growth and Advances C-PTBE-01 Development

Curatis Holding AG reported a 14% year-on-year revenue increase to CHF 5.2m for the first half of 2025. This growth was bolstered by a significant partnership with Phoenix Labs, contributing CHF 5m in 2024 revenues. Despite these gains, the company recorded a loss of CHF 1.2m, impacted by increased development expenses for its lead product candidate, C-PTBE-01, a treatment for peritumoral brain edema.

The meeting with the FDA on 9 September 2025 yielded a positive outcome, aligning on the Phase III trial design for C-PTBE-01. Curatis began seeking global pharmaceutical partners for C-PTBE-01 in Q3 2025. The company maintains a cash position of CHF 2.0m and aims for a break-even result in 2026 through increased revenues and cost reduction, irrespective of the partnering status for C-PTBE-01.